RNTX
Rein Therapeutics Inc
NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY
$0.66
-1.32% today
Updated 2026-11-04
Market cap
$50.31M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.68
Dividend yield
—
52W range
$1 – $2
Volume
0.4M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-28.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$6.00
+810.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -28.85 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-8.64M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27329.00 | $-15732.00 | $-62.88M | $-49.87M | $-6.38M |
| EPS | — | — | — | — | $-1.68 |
| Free cash flow | $-24.86M | $-19.81M | $-22.29M | $-19.36M | $-8.64M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Rein Therapeutics Inc trades at $0.66. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -28.85, it sits in the distress.
Frequently asked questions
What is Rein Therapeutics Inc's stock price?
Rein Therapeutics Inc (RNTX) trades at $0.66.
Is Rein Therapeutics Inc overvalued?
Rein Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Rein Therapeutics Inc (RNTX)?
The 12-month analyst consensus target is $6.00, about 810.9% above the current $0.66. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Rein Therapeutics Inc's Altman Z-Score is -28.85, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-163.40%
Beta1.36
50D MA$0.75
200D MA$1.05
Shares out0.09B
Float0.07B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—